Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
| Authors | |
|---|---|
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Haematologica |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.haematologica.org/content/101/3/263.full.pdf+html |
| Doi | http://dx.doi.org/10.3324/haematol.2015.139246 |
| Field | Oncology and hematology |
| Keywords | CLONAL EVOLUTION; MUTATIONS; SURVIVAL; TRIAL; PROGRESSION; IMPACT; CLL |
| Description | T he prognostication of patients with chronic lympho- cytic leukemia (CLL) currently relies on both clinical and biological parameters (Figure 1). The prime exam- ple concerns the TP53 gene, whereby inactivation of TP53 , resulting from either a mutation or chromosome 17p deletion, is associated with a short time to progression, an early need for treatment, and an overall dismal outcome. 1,2 The presence of TP53 aberrations is also a strong predictor of treatment response, as patients carrying such lesions respond poorly to standard chemoimmunotherapy (CIT) (i.e. fludarabine, cyclophosphamide, and rituximab). 3 Although TP53 abnor- malities are infrequent at diagnosis (5%-10%), they are found in 40%-50% of advanced or therapy-refractory cases, hence underscoring the need to re-assess TP53 gene status as the dis- ease progresses and clones evolve. |
| Related projects: |